全文获取类型
收费全文 | 105篇 |
免费 | 1篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 11篇 |
基础医学 | 11篇 |
临床医学 | 5篇 |
内科学 | 12篇 |
神经病学 | 14篇 |
特种医学 | 4篇 |
外科学 | 6篇 |
综合类 | 1篇 |
预防医学 | 4篇 |
药学 | 2篇 |
肿瘤学 | 36篇 |
出版年
2022年 | 1篇 |
2021年 | 3篇 |
2019年 | 2篇 |
2018年 | 1篇 |
2017年 | 2篇 |
2016年 | 2篇 |
2015年 | 3篇 |
2014年 | 5篇 |
2013年 | 8篇 |
2012年 | 14篇 |
2011年 | 8篇 |
2010年 | 5篇 |
2009年 | 3篇 |
2008年 | 7篇 |
2007年 | 5篇 |
2006年 | 5篇 |
2005年 | 8篇 |
2004年 | 9篇 |
2003年 | 6篇 |
2002年 | 5篇 |
2001年 | 2篇 |
1998年 | 2篇 |
1995年 | 1篇 |
排序方式: 共有107条查询结果,搜索用时 31 毫秒
1.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
2.
Tsui-Lien Hung Fen-Fen Chen Jacqueline M Liu Wu-Wei Lai Ai-Li Hsiao Wen-Tsung Huang Helen H W Chen Wu-Chou Su 《Clinical cancer research》2003,9(7):2605-2612
PURPOSE: Lung adenocarcinoma presenting as malignant pleural effusion (MPE) is common in Taiwan. Microscopically, the involved pleurae are infiltrated by numerous tumor foci, which suggests that the cancer cells are highly invasive. Overexpression of HER-2/neu has been related to proliferation, antiapoptosis, and the high invasiveness of various cancer cells. We therefore were interested in studying the role of HER-2/neu in MPE-associated adenocarcinoma cell lung cancer (ADCLC). Experimental Design: The expression of HER-2/neu in pleural effusion was measured by ELISA. The HER-2/neu protein expression on tumor cells was evaluated by immunohistochemical (IHC) staining, and gene amplification was assayed by fluorescence in situ hybridization. RESULTS: The mean value of HER-2/neu in pleural effusions of patients with ADCLC and other nonmalignant lung diseases was 9.9 and 2.7 ng/ml, respectively. The difference is statistically significant (P < 0.001). Compared with cytokeratin 19 fragment CYFRA 21-1, the performance of HER-2/neu as a tumor marker in pleural effusion diagnosis was better. Overexpression of HER-2/neu in tumor tissues was found in 70% (23 of 32) of patients with MPE-associated ADCLC, 30% (13 of 43) with stage I/II non-small cell lung cancer (NSCLC), and 44% (14 of 32) with stage III NSCLC. The incidence of HER-2/neu overexpression in tumor tissues of patients with MPE-associated ADCLC was significantly higher than that of patients with stage I-III NSCLC without MPE. HER-2/neu gene amplification was uncommon (1.9%). The correlation between the IHC H-score in tumor samples and the pleural effusion level of HER-2/neu was significant (P < 0.01). A higher incidence of HER-2/neu expression beyond the cutoff point (5.5 ng/ml) in pleural effusions was also found in patients whose IHC H-scores were >50. CONCLUSIONS: These findings indicate that HER-2/neu is important in the pathogenesis of MPE-associated ADCLC and is a potential tumor marker for a diagnosis of pleural effusion. 相似文献
3.
Shang-Yin Wu Yu-Min Yeh Ya-Ping Chen Wu-Chou Su Tsai-Yun Chen 《Annals of hematology》2012,91(11):1773-1778
Thromboembolism (TE) is a common complication in patients with multiple myeloma (MM). Immunomodulatory agents, e.g., thalidomide, have expanded the therapeutic options for treating myeloma; however, Western countries report a high incidence of thrombosis in thalidomide-treated MM patients who lack thromboprophylaxis. A Korean trial reported low TE incidence in thalidomide-treated myeloma patients (39?% were given aspirin prophylactically). We aimed to elucidate the TE frequency in MM patients in Taiwan who were treated with thalidomide without TE prophylaxis. We retrospectively collected the records of MM patients who had used thalidomide from a single institute between 2004 and 2010, combined these records with two other Taiwanese studies, and compared all three with the Korean trial. In the current Taiwanese series, five of 144 patients (3.5?%) developed TE as follows: three (2.1?%) were venous and two (1.3?%) were arterial. Only 6.1?% of the patients had undergone TE prophylaxis, which is less than in the Korean trial (38.9?%, p?<?0.05). Of the patients in the relapsed/refractory cohort (n?=?114) who were given thalidomide alone, none (0/52) developed venous TE (VTE); however, two patients (2/35, 5.7?%) who were given thalidomide–dexamethasone as a salvage treatment developed VTE. In the thrombosis cohort, four patients (80?%) were treated with thalidomide plus dexamethasone. In conclusion, the frequency of thalidomide-related TE in myeloma patients without effective TE prophylaxis was low in Taiwan. In relapsed/refractory myeloma patients, the VTE frequency was slightly lower compared with Western patients irrespective of treatment with thalidomide alone or combined with dexamethasone. Even in low TE incidence areas, thalidomide combined with dexamethasone was more thrombogenic compared with others. 相似文献
4.
Kuo-Hsuan Hsu Kun-Chieh Chen Tsung-Ying Yang Yi-Chen Yeh Teh-Ying Chou Hsuan-Yu Chen Chi-Ren Tsai Chih-Yi Chen Chung-Ping Hsu Jiun-Yi Hsia Cheng-Yen Chuang Ying-Huang Tsai Kuan-Yu Chen Ming-Shyan Huang Wu-Chou Su Yuh-Min Chen Chao A. Hsiung Gee-Chen Chang Chien-Jen Chen Pan-Chyr Yang 《Journal of thoracic oncology》2011,6(6):1066-1072
5.
Bonifati V Wu-Chou YH Schweiger D Fonzo AD Lu CS Oostra B 《Neurology》2008,70(24):2348; author reply 2348-2348; author reply 2349
6.
7.
Tsung-I Hsu Ying-Jung Chen Chia-Yang Hung Yi-Chang Wang Sin-Jin Lin Wu-Chou Su Ming-Derg Lai Sang-Yong Kim Qiang Wang Keduo Qian Masuo Goto Yu Zhao Yoshiki Kashiwada Kuo-Hsiung Lee Wen-Chang Chang Jan-Jong Hung 《Oncotarget》2015,6(15):13671-13687
Herein, we evaluated the anti-cancer effect and molecular mechanisms of a novel betulinic acid (BA) derivative, SYK023, by using two mouse models of lung cancer driven by KrasG12D or EGFRL858R. We found that SYK023 inhibits lung tumor proliferation, without side effects in vivo or cytotoxicity in primary lung cells in vitro. SYK023 triggered endoplasmic reticulum (ER) stress. Blockage of ER stress in SYK023-treated cells inhibited SYK023-induced apoptosis. In addition, we found that the expression of cell cycle-related genes, including cyclin A2, B1, D3, CDC25a, and CDC25b decreased but, while those of p15INK4b, p16INK4a, and p21CIP1 increased following SYK023 treatment. Finally, low doses of SYK023 significantly decreased lung cancer metastasis in vitro and in vivo. Expression of several genes related to cell migration, including synaptopodin, were downregulated by SYK023, thereby impairing F-actin polymerization and metastasis. Therefore, SYK023 may be a potentially therapeutic treatment for metastatic lung cancer. 相似文献
8.
Wu-Chou Lin Ming-Tsung Lai Huey-Yi Chen Chien-Yi Ho Kee-Ming Man Jui-Lung Shen Yuan-Ju Lee Fuu-Jen Tsai Yung-Hsiang Chen Wen-Chi Chen 《Urological research》2012,40(6):655-661
Flos carthami (FC), also known as Carthamus tinctorius, is a traditional Chinese herbal plant that has been prescribed since centuries for treating various symptoms related to blood circulation improvement. This study aimed to investigate the effects of FC on calcium oxalate (CaOx) formation in ethylene glycol (EG)-fed rats. A total of 50 male Sprague–Dawley rats were divided into the following 6 groups: group 1, as the normal control (n?=?5); group 2 received gastric gavages of starch and 0.75% EG (placebo, n?=?5) as a stone inducer; group 3 (n?=?10) received EG and potassium citrate as positive controls; group 4 (n?=?10) received 0.75% EG and 300?mg/day FC; group 5 (n?=?10) was treated with EG and 600?mg/day FC; group 6 (n?=?10) received with EG and 1,200?mg/day FC. For all experimental animals, 24-h urine and blood samples were analyzed at the beginning and end of the experiment. Kidney tissue was histopathologically examined using a polarized light microscope, and crystal deposits were evaluated by a semi-quantitative scoring method; these scores were significantly lower in the FC groups (600 and 1,200?mg/day) than in the placebo group. Thus, FC administration appeared to inhibit the deposition of CaOx crystal EG-fed rats. We, therefore, consider that FC may be effective for preventing stone disease, albeit with certain side effects, such as a bleeding tendency. Further clinical trials are needed for evaluating its benefits and possible side effects. 相似文献
9.
Parastoo Momeni Chin-Song Lu Yah-Huei Wu Chou Hsiu-Chen Chang Rou-Shayn Chen Chiung-Chu Chen Jin-Tian Hsu Andrew Singleton John Hardy 《Movement disorders》2005,20(12):1633-1636
We have assessed the haplotypes at the ATXN2 locus in Taiwanese controls and in individuals with SCA2 ataxia with both ataxic and parkinsonian features. Our intention was to determine whether a different ataxin 2 haplotypes predisposed to the two phenotypes. In fact, our analysis showed that all SCA2 mutations carriers had the same ataxin 2 haplotype: haplotype B, which accounts for only 15% of control haplotypes, implying that there is a common founder for all Taiwanese SCA2 patients. 相似文献
10.
Shi M Murray JC Marazita ML Munger RG Ruczinski I Hetmanski JB Wu T Murray T Redett RJ Wilcox AJ Lie RT Jabs EW Wu-Chou YH Chen PK Wang H Ye X Yeow V Chong SS Shi B Christensen K Scott AF Patel P Cheah F Beaty TH 《American journal of medical genetics. Part A》2012,(4):784-794
We performed a genome wide association analysis of maternally-mediated genetic effects and parent-of-origin (POO) effects on risk of orofacial clefting (OC) using over 2,000 case-parent triads collected through an international cleft consortium. We used log-linear regression models to test individual SNPs. For SNPs with a P-value <10(-5) for maternal genotypic effects, we also applied a haplotype-based method, TRIMM, to extract potential information from clusters of correlated SNPs. None of the SNPs were significant at the genome wide level. Our results suggest neither maternal genome nor POO effects play major roles in the etiology of OC in our sample. This finding is consistent with previous genetic studies and recent population-based cohort studies in Norway and Denmark, which showed no apparent difference between mother-to-offspring and father-to-offspring recurrence of clefting. We, however, cannot completely rule out maternal genome or POO effects as risk factors because very small effects might not be detectable with our sample size, they may influence risk through interactions with environmental exposures or may act through a more complex network of interacting genes. Thus, the most promising SNPs identified by this study may still be worth further investigation. 相似文献